Unless otherwise stated, all references are to the Abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases (57th AASLD), October 27-31, 2006, Boston, MA.

Please note that the material posted here by HIV and Hepatitis.com here is not approved by nor is it a part of the 57th AASLD or the American Association for the Study of Liver Diseases.



Faneuil Hall

Links to
Website Sponsors


State House

 

 

Hepatitis C
Library of Slides and Posters

FDA-approved Combination Therapy
Pegasys + Copegus
- (peginterferon alfa-2a + ribavirin)
PegIntron + Rebetol
- (peginterferon alfa-2b + ribavirin)

ALT / AST and ALT / AST Ratio (AAR)
Clinical Trials
Epidemiology
Experimental Treatments

Genotypes

HCV Viral Load

HIV-HCV Coinfection

Liver Issues

Nonresponders / Relapsers / Re-treatment
Risk Factors
Sustained Viral Response (SVR)

Weight-based Dosing

Hepatitis B
Library of Slides and Posters

FDA-approved Therapy
Tyzeka (telbivudine)
Baraclude (entecavir)
Hepsera (adefovir dipivoxil)
 

ALT / AST and ALT / AST Ratio (AAR)
Clinical Trials

Experimental Treatments
HBeAg Positive / HBeAg Negative
HBV Recurrence
HBV Resistance
HBV Viral Load
Liver Issues / Transplantation